Monitoring the long-term use of JARDIANCE in patients with chronic kidney disease
Post Marketing Surveillance on Long Term Use of JARDIANCE® Tablets in Patients With Chronic Kidney Disease in Japan
This study is testing how well JARDIANCE works and how safe it is for people with chronic kidney disease who are starting this medication for the first time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Boehringer Ingelheim Industry-sponsored |
| Locations | 1 site (Tokyo) |
| Trial ID | NCT06527846 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety and effectiveness of JARDIANCE® Tablets in patients diagnosed with chronic kidney disease (CKD) in a real-world setting. Participants will be those who have been prescribed JARDIANCE® for CKD and have not previously received this medication. The study will collect data on the long-term daily use of the drug to assess its impact on kidney health. The findings will help inform future treatment guidelines and patient management strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with chronic kidney disease who are newly prescribed JARDIANCE® Tablets.
Not a fit: Patients who have previously been treated with JARDIANCE® for any condition will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of JARDIANCE for patients with chronic kidney disease.
How similar studies have performed: While this study focuses on post-marketing surveillance, similar studies have shown promising results in evaluating the long-term effects of medications in chronic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study. * Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment. Exclusion Criteria: * None
Where this trial is running
Tokyo
- Nippon Boehringer Ingelheim Co., Ltd. — Tokyo, Japan (Recruiting)
Study contacts
- Study coordinator: Boehringer Ingelheim
- Email: clintriage.rdg@boehringer-ingelheim.com
- Phone: 1-800-243-0127
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.